128940:KRXHanmi Pharm. Co., Ltd. Analysis

Hanmi Pharm. is trading at a price of 536,000 KRW, which sits well above its DCF‑derived fair value of roughly 28,900 KRW, indicating a material overvaluation. The stock’s RSI of 64 suggests continued buying pressure but is approaching overbought territory, while the MACD histogram of +12,810 confirms a bullish momentum shift. However, volatility remains high at over 60% (30‑day) and the max drawdown of ‑34% signals susceptibility to sharp declines. Valuation metrics reinforce the premium: a forward PE of nearly 32 versus an industry average of 27, and a price‑to‑sales multiple above 4. The dividend yield is modest at 0.37% with a low payout ratio, supporting sustainability but offering limited income appeal.
Given the neutral trend direction, increasing volume, and strong market cap, the stock may sustain short‑term momentum, yet the disparity between market price and intrinsic value, coupled with sector regulatory sensitivities, suggests caution for longer horizons.